Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pidimol-MF
- Development stage
- Phase 2
- Lead developer
- Octave Life Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pidimol-MF is an oral suspension (syrup) formulation containing a combination of mefenamic acid and paracetamol (acetaminophen). Developed and marketed by Octave Life Sciences, it is primarily used as an analgesic and antipyretic to relieve mild to moderate pain, inflammation, and fever, particularly in pediatric patients. Mefenamic acid is a non-steroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing the synthesis of inflammatory prostaglandins. Paracetamol acts as a centrally-mediated analgesic and antipyretic, complementing the peripheral anti-inflammatory action of mefenamic acid. Together, they provide synergistic relief from fever, headaches, toothaches, muscle aches, and post-vaccination discomfort.
- Brand names
- Pidimol-MF
- Other names
- mefenamic acid + paracetamolmefenamic acid + paracetamol suspensionmefenamic acid and paracetamol suspension
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Pidimol-MF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pidimol-MF.